Agape ATP (NASDAQ:ATPC), Inc. (NASDAQ: ATPC) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel immuno-oncology therapies. Headquartered in Boston, Massachusetts, the company was founded in 2018 through a merger of several early-stage life science ventures and has since built a diversified pipeline centered on oncolytic virus platforms and immune-modulating biologics. Agape ATP’s mission is to harness the body’s natural defense mechanisms to target and destroy cancerous cells while minimizing toxicity to healthy tissues.
The company’s product portfolio includes a lead oncolytic adenovirus candidate designed to selectively infect and lyse tumor cells and stimulate a systemic anti-tumor immune response. In addition, Agape ATP maintains a preclinical immunomodulator program based on engineered cytokine fusion proteins, which are intended to enhance the efficacy of checkpoint inhibitors in solid tumors. By leveraging proprietary viral delivery systems and next-generation protein engineering, the company aims to address cancer types with high unmet medical need, including pancreatic, ovarian and hepatocellular carcinomas.
Agape ATP conducts its research and development activities in state-of-the-art laboratories in the Greater Boston area, with manufacturing collaborations in the United States and Europe. The company has established strategic partnerships with leading academic institutions and contract research organizations to accelerate preclinical validation and early-phase clinical trials. While its initial focus is on North America and Western Europe, Agape ATP is exploring regulatory pathways and commercialization collaborations in Asia-Pacific markets to broaden patient access and global reach.
The leadership team is led by President and Chief Executive Officer Dr. John Reynolds, a seasoned biotech executive with more than two decades of experience in oncology drug development. Chief Scientific Officer Dr. Maria Chen oversees Agape ATP’s research programs, having previously led translational immunology efforts at a major pharmaceutical firm. Supported by a board of directors with deep expertise in corporate finance, regulatory affairs and oncology, Agape ATP is strategically positioned to advance its therapeutic candidates through clinical milestones and toward potential partnerships or licensing agreements.
